Basel-based startup KetoSwiss raises USD 4.8 million in pre-series A funding to propel medical food solution for migraine

04.08.2023 18:41, Rita Longobardi

Specialized in medical food for migraine and related neurological disorders, KetoSwiss has successfully concluded a second closing of its pre-series A financing round, securing a total capital of USD 4.8 million. With its flagship product MigraKet, the company aims to address the root cause of migraine through a novel dietary-preventive therapy, offering a clinically tested and patent-protected solution.

KetoSwiss has successfully concluded the second closing of its pre-series A financing round, amassing a total of USD 4.8 million in capital. The company is now poised to drive forward its developments and introduce its flagship product, MigraKet, to the market.

With approximately one billion people worldwide affected by migraine, the absence of medical solutions targeting the root cause presents a significant challenge. In response, KetoSwiss has pioneered an innovative medical food designed for the dietary-preventive therapy of migraine and related conditions characterized by metabolic dysfunction. This innovative approach aims to establish KetoSwiss as a key player in the medical food market while simultaneously pursuing further research and development opportunities in potential drug avenues.

MigraKet, the company's first flagship product under the Brain Ritual brand, combines the brain's ancient fuel with essential micronutrients critical for optimal brain energy metabolism. KetoSwiss takes pride in offering a comprehensive, clinically tested, and patent-protected solution. Building upon last year's investments from various backers to propel product development, KetoSwiss has secured an additional USD 0.8 million this year, culminating in a remarkable total capital raised of USD 4.8 million for the pre-series A round.

KetoSwiss participated in Venture Leaders Life Sciences in 2020.


Dr. Elena Gross, Founder & CEO of KetoSwiss